Drugs / Lucanix
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01058785 | Mar 2003 → Dec 2005 | bronchogenic carcinoma | NovaRx Corporation | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00676507 | Jul 2008 → Jan 2013 | non-small cell lung carcinoma | NovaRx Corporation | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lucanix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00676507 ↗ |
| Action | Inhibit | “gene modify these tumor cells in the laboratory to block their TGF-beta secretion.” NCT01058785 ↗ |
| Route | Other | “Subjects receive belagenpumatucel-L (Lucanix™) intradermally (ID)” NCT00676507 ↗ |
| Target | TGFB2 | “TGF-beta2 antisense gene modified NSCLC cell lines” NCT01058785 ↗ |